San­doz opens two new fa­cil­i­ties; Gates Foun­da­tion funds nee­dle-free vac­cines; No­var­tis ex­pands Japan­ese site

Last year
Manufacturing

Biotech’s IPO out­look for the rest of the year sours in wake of war, broad­er in­dus­try strug­gles

Last year
Financing
Startups

Spring­Works eyes US fil­ing for MEK in­hibitor af­ter pos­i­tive PhI­Ib da­ta in rare dis­ease

Last year
R&D

Am­gen lines up new AI biotech part­ner in PostEra to de­vel­op small mol­e­cule med­i­cines

Last year
Deals
AI

Q32 Bio to take Ho­mol­o­gy Med­i­cines’ Nas­daq spot to fund PhII tri­als in au­toim­mune, in­flam­ma­to­ry con­di­tions

Last year
Startups
Deals

Scoop: Rakuten Med­ical tar­gets year-end close for $100M+ Se­ries E to fund pho­toim­munother­a­py pipeline: #Jef­feries23

Last year
Financing
R&D

FDA hands down ap­proval for Bris­tol My­er­s' lung can­cer drug from Turn­ing Point buy­out

Last year
Pharma
FDA+

In a world first, Ver­tex, CRISPR win UK ap­proval for CRISPR-edit­ed ther­a­py to treat sick­le cell dis­ease, ...

Last year
Cell/Gene Tx
FDA+

Heard at #Jef­feries23: Al­ny­lam, Bi­cy­cle, In­tel­lia, Nous­com, Rakuten Med­ical ex­ecs fore­cast 2024

Last year
People
Pharma

Astel­las bags prostate can­cer drug in $175M buy­out as Xtan­di ap­proach­es patent cliff

Last year
Deals

In­vestors Or­biMed and Fore­site say they're look­ing at tak­ing Kin­nate pri­vate, fol­low­ing pipeline and staff cuts

Last year
Deals

No­vo Nordisk launch­es head-to-head tri­al with Eli Lil­ly as weight loss ri­val­ry heats up

Last year
Pharma

Phar­mas and physi­cians val­ue med­ical af­fairs and MSLs, but have dif­fer­ent con­tent pri­or­i­ties, sur­vey says

Last year
Pharma
Marketing

Ozem­pic short­ages have Eu­ro­pean coun­tries ex­plor­ing bans on use of pop­u­lar drug for weight loss

Last year
Pharma
Manufacturing

CorMedix wins US ap­proval via rarely-used path­way for drug to re­duce blood­stream in­fec­tions

Last year
Pharma
FDA+

Sanofi hands out com­mu­ni­ty health eq­ui­ty grants in on­go­ing ef­fort to build trust with mar­gin­al­ized groups

Last year
Pharma
Marketing

A Mark Cuban copy? Cigna’s Ex­press Scripts to of­fer what it calls an­oth­er cost-plus pric­ing mod­el

Last year
Pharma
Health Tech

Eli Lil­ly wins pre­lim­i­nary in­junc­tion in Moun­jaro case in drug­mak­er­s' on­go­ing bat­tle with com­pound­ing phar­ma­cies, ...

Last year
Pharma
Marketing

Gen­er­ate:Bio­med­i­cines opens the hood on its AI soft­ware for mak­ing pro­teins

Last year
R&D
AI

Can post-mar­ket ev­i­dence gen­er­a­tion be stream­lined? FDA-com­mis­sioned re­port pro­pos­es so­lu­tions

Last year
Pharma
FDA+

FDA rais­es con­cerns over ef­fi­ca­cy of Mer­ck­'s po­ten­tial chron­ic cough drug ahead of ad­comm

Last year
Pharma
FDA+

Is the worst over? Catal­ent touts GLP-1 and gene ther­a­py busi­ness as it sticks to fi­nan­cial guid­ance

Last year
Manufacturing

Scoop: Cell­Prothera eyes $30M round for PhI­II tri­al of cell ther­a­py for heart at­tacks: #Jef­feries23

Last year
Financing
Cell/Gene Tx

Gilde Health­care's €140M; EMD Serono to move US HQ to Boston; Arc­turus up for $35M mile­stone

Last year
News Briefing
First page Previous page 244245246247248249250 Next page Last page
A service from the Financial Times